Table 4 Univariate analysis of baseline characteristics to determine associations with disease severity in patients with multiple sclerosis.

From: The periodontal pathogen Fusobacterium nucleatum is associated with disease severity in multiple sclerosis

Ā 

EDSS score ≄ 4.0

(N = 16)

EDSS score < 4.0

(N = 40)

p value

Age, years

56 ± 11.2

43.3 ± 12.3

< 0.001*

Sex (female), n (%)

12 (75)

31 (77.5)

0.841

Disease duration, years

19.0 ± 8.8

11.2 ± 8.7

0.004*

Current smoking, n (%)

2 (12.5)

3 (7.7)

0.573

Current dental visiting, n (%)

9 (56.3)

12 (30.8)

0.077

High relative abundance of F. nucleatum, n (%)

8 (50.0)

5 (12.5)

0.003*

MS subtype

Ā Ā 

< 0.001*

RRMS, n (%)

8 (50.0)

38 (95.0)

Ā 

SPMS, n (%)

8 (50.0)

2 (5.0)

Ā 

Number of attacks

4.2 ± 4.8

2.2 ± 2.6

0.046

Relapse within one year, n (%)

3 (18.8)

5 (12.5)

0.546

MRI findings

Periventricular, n (%)

16 (33.3)

32 (80.0)

0.053

Cortical or juxtacortical, n (%)

11 (68.8)

30 (75.0)

0.633

Infratentorial, n (%)

13 (81.3)

28 (70.0)

0.390

Spinal cord, n (%)

13 (81.3)

29 (72.5)

0.495

DMD

Ā Ā 

0.427

Low-efficacy treatment or drug free, n (%)

7 (43.8)

13 (32.5)

Ā 

High-efficacy treatment, n (%)

9 (56.3)

27 (67.5)

Ā 
  1. The data are presented as the means ± standard deviations or medians (minimum values, maximum values) for continuous variables and as frequencies and percentages for discrete variables. Low-efficacy treatments include beta-interferon, glatiramer acetate, and dimethyl fumarate; high-efficacy treatments include natalizumab, ofatumumab, and fingolimod.
  2. *p < 0.05.
  3. Abbreviations: EDSS, Expanded Disability Status Scale; F. nucleatum, Fusobacterium nucleatum; MS, multiple sclerosis; RRMS, relapsing–remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; MRI, magnetic resonance imaging; DMD, disease-modifying drug.